- Home
- RMTI vs RFL Comparison
RMTI vs RFL Comparison
Compare RMTI & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMTI | RFL |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 54.4M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | RMTI | RFL |
|---|---|---|
| Price | $0.92 | $1.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 227.0K | 143.0K |
| Earning Date | 11-12-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $75,577,000.00 | $1,029,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 47.63 |
| 52 Week Low | $0.78 | $1.17 |
| 52 Week High | $2.41 | $3.19 |
Technical Indicators
Market Signals| Indicator | RMTI | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 43.56 | 64.11 |
| Support Level | $0.87 | $1.21 |
| Resistance Level | $0.97 | $1.60 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 34.62 | 67.44 |
Price Performance
Historical ComparisonAbout RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.